genasense implications

Genta Inc will hold an open meeting for investors and analysts in New York on Wednesday (NY Time), at which it will present an update on results of the
Phase 3 Randomised Clinical Trial of Genasense(TM) (oblimersen sodium).

PARIS, Sept 8 (Reuters) - Franco-German drugmaker Aventis (AVEP.PA) said on Monday it expected to decide in coming weeks whether to apply this year
for U.S. marketing approval for cancer drug Genasense, which it is developing with Genta Inc.

"We anticipate in a matter of weeks to be in a position to determine whether we can file this year for one of the three lead indications," Aventis Vice President for Drug Innovation Frank Douglas said during a conference call after the company said it had bought rights to another experimental cancer drug.

Will keep an eye out for this one.